Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease.
Journal: The New England journal of medicine
Published: April 03, 2026
Dynamics of complete responses (CRs) in patients with relapsed or refractory follicular lymphoma (R/R FL) treated with odronextamab in the ELM-2 study.
Journal: HemaSphere
Published: June 02, 2025
Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Journal: Nature cancer
Published: April 16, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 Study.
Journal: Clinical lymphoma, myeloma & leukemia
Published: February 19, 2025
Prognostic Factors and Effect Modifiers in Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma After Two Lines of Therapy: A Systematic Literature and Expert Clinical Review.
Journal: European journal of haematology
Published: February 03, 2025
Corrigendum to "Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma": [Ann Oncol 35 (2024) 1039-1047].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 03, 2024
Reply to the Letter to the Editor "Odronextamab against relapsed or refractory follicular lymphoma" by Y. Shimazu.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: September 24, 2024
Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.
Journal: Nature cancer
Published: August 14, 2024
Last Updated: 09/26/2026